LungLife AI, Inc. (GB:LLAI) has released an update.
LungLife AI, Inc. has announced the acceptance of two abstracts related to its LungLB test by the Association for Molecular Pathology for presentation and publication. These abstracts, which confirm the test’s analytic and clinical validity, will be featured at the AMP’s Annual Meeting & Expo and in The Journal of Molecular Diagnostics. The company views this as a crucial step towards the commercialization of LungLB, a blood-based diagnostic test aimed at early detection of lung cancer.
For further insights into GB:LLAI stock, check out TipRanks’ Stock Analysis page.
